NuvoBio’s Post

SPU-16 Regulatory Pathway: May be used for diagnosing and monitoring #MS Decreases toxicity of existing therapeutics May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord Learn more here: https://lnkd.in/g5us5zxz #BioTech #Science

Congratulations to Edinburgh-based #biotech Cytomos who has raised £5M to scale up production of its cell analysis technology. The round was led by existing investors Archangel Investors Limited with participation from Old College Capital, Scottish Enterprise and the British Business Bank. The capital will be invested in marketing Cytomos its first commercial product, #Celledonia™, built on its cell-analysis technology platform AuraCyt. Celledonia™ is a benchtop cell analyser which aims to significantly enhance single-cell analysis, potentially transforming biological drug discovery, development processes, and biologics manufacturing. The business' sights are now set on establishing a foothold in North America, the company has a pipeline of trials planned with global partners and strong interest in co-development opportunities from technology developers and a #pharma company. Cytomos' technology #AuraCyt is an unbiased, scalable cell analysis platform to provide a scalable alternative to current cell analysis systems. Using this platform, Cytomos enables biopharma to bring novel therapies to market by up to 6 months faster and reduce costs by enabling critical decision making earlier. Its scalable nature makes it unique in measuring cellular physiology based on intrinsic single-cell properties. Find out more via tech.eu https://lnkd.in/ebBfms2c #Biotech #CellAnalysis #Cytomos #Biopharma #EdinburghTech #DrugDiscovery #Biologics #SingleCellAnalysis #HealthTech #Innovation

Ten Companies to Watch in AI Drug Discovery https://lnkd.in/gCWtSdiZ In AI-based drug discovery—a field benefiting from a cumulative investment of $60 billion—the leaders are making real progress toward approved therapies. The post Ten Companies to Watch in AI Drug Discovery appeared first on GEN [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

🌟 Exciting News for Glycoscientists! 🌟 We are thrilled to announce that we have 1 kg of UDP-GalNAz (Uridine diphosphate N-acetylgalactosamine azide) in stock and ready for your research needs! UDP-GalNAz is essential for: 🔬 Glycan labeling and visualization 🔬 Studying glycosylation processes 🔬 Advancing drug development 🔬 Discovering glycan biomarkers Whether you're conducting cutting-edge research or developing new therapeutics, our high-quality UDP-GalNAz can help accelerate your projects. Visit our website to order or contact us for more information. #Glycoscience #Research #UDPGalNAz #Biotechnology #Innovation #Glycoengineering #ADC

The life sciences sector is experiencing robust growth in areas such as gene and cell therapies, biologics, and vaccines, even amid challenges such as high costs, talent shortages, regulatory hurdles, and scarcity of raw materials. According to WTW's survey of 400 leading decision-makers in the industry, companies are venturing into new markets and embracing automation to enhance efficiency. Looking forward, the industry is increasingly concentrating on introducing new products, expanding into international markets, and leveraging automation and intelligent manufacturing to boost efficiency and tackle workforce issues. Download report for the full survey findings: https://ow.ly/5kuJ50SxFvy #WTWDirectandFac #LifeSciences #Pharma #RiskManagement #Biotech #Innovation

PROTAC leverages the capacity of targeted protein degradation to change protein function and treat complex illnesses revolutionizing the field of drug discovery. Targeted protein degradation (TPD) has also gained much attention from researchers, offering new opportunities to target protein traditionally defined as "non-druggable"   Sphaera Pharma collaborates with biotech to provide PROTAC chemistry expertise to target disease-causing proteins and develop innovative therapeutic solutions.   Reach out to us at bd@sphaerapharma.com to learn more about our capabilities, collaboration models, and opportunities. #PROTAC #TargetedProteinDegradation #DrugDiscovery #SphaeraPharma

The Biotech Boom: Why 2025 is a Year of Opportunity Did you know the global #biotechnology market is projected to reach $3 trillion by 2030? This incredible growth is being driven by advancements in precision medicine, regenerative therapies, and cutting-edge pharmaceutical innovation. At Stella Consultancy, we are thrilled to play a role in this transformation. Our team has been collaborating with partners in Serbia and across Europe to explore groundbreaking projects that align with these trends. From fostering partnerships in personalized healthcare to promoting sustainable investment opportunities, we’re bridging global expertise with local innovation. 💡 One area we're especially excited about? The rise of #Bio4 in Serbia, a promising platform poised to position the region as a biotech hub. With its focus on #genomics, #biomedicine, and #bioinformatics, the future of biotech is closer than ever! Join us as we #connect, #innovate, and #grow in this exciting sector. What trends in biotech are you following closely? Let’s discuss! #Biotech #StellaConsultancy #Innovation #Pharma #SerbiaBiotech

The biopharma industry is evolving rapidly with the emergence of new technologies and methodologies 🔬 MarketsandMarkets™ projects that the global biotech market, driven by groundbreaking advancements and innovative approaches, will reach $465.9 billion in 2024. In our latest article, Roman Bevz, our Head of Business Consulting and Advisory Practice, explores these advancements shaping the sector 🔍 Discover the latest trends in #biopharma, including AI-driven drug discovery, personalized medicine, and other transformative technologies. 🖇️ https://lnkd.in/dQcSqNyE  #Avenga  #AvengaInsights #Biotech #PersonalizedMedicine #TechTrends  

🔬✨ In this week's #TechTales post, we highlight our MOF-based nano-shuttle technology and its role in efficient drug delivery. Drug delivery involves several complex steps to ensure the therapeutic agent reaches its target effectively. Our drug-loaded #NanoShuttles first target and bind to specific cell types. Once the delivery system is bound to the cell surface, the cell internalises it through a process called endocytosis. The delivery system then needs to escape the endosome to release the drug into the cytoplasm. Slow drug release is another essential aspect of our technology. By controlling the release of the drug, we avoid the burst effect, which can lead to rapid, uncontrolled drug release, causing side effects and reduced efficacy. Controlled release ensures steady therapeutic levels over time, enhancing treatment effectiveness and patient outcomes. Stay tuned for our next #TechTales post as we continue to explore the science driving our innovations. 🚀🔗 #DrugDelivery #Nanotechnology #Biopharma #Biotech #HealthcareRevolution

In this insightful session with Matthew Cook, Senior Director Sales - UK, Ireland Nordics (Academia, Public & Pharma) at Merck Life Science | CSAM, we explored the evolving landscape of advanced therapies, including cell and gene therapies. Mathew discussed the strategic shifts needed to make these innovations widely accessible, the key factors investors should consider in this space, and the market barriers companies face when scaling from niche treatments to broader applications, and the ways to overcome them. Mathew also shared insights on how companies can differentiate their offerings beyond clinical efficacy to build a sustainable business model in a competitive market. Read more here https://lnkd.in/gb3YxraM #lbs #lbs25 #londonbiotechnologyshow #biotechnology #bioinformatics #medtech #innovation #lifesciences #healthcare #pharmaceutical #biomedicalengineering #tissueengineering #biotechconference #biotechevent #biotechexpo #redbiotechnology #excellondon #londonbiotech